Related Experiment Videos
Piperacillin-tazobactam treatment for severe intra-abdominal infections
J C Legrand1, F Bastin, P Belva
1Department of Internal Medicine, Hôpital Civil de Charleroi, Belgium.
Abstract:
In this limited series of 23 patients suffering from severe or life-threatening intra-abdominal infection, piperacillin + tazobactam, together with adequate surgical drainage and resections, cured 78% of our patients and eradicated almost all the pathogens. Side effects included essentially eosinophilia and elevation of transaminases but was never severe. Piperacillin + tazobactam seem thus to be an acceptable treatment, associated with correct surgical drainage. This regimen has to be compared in appropriate trial versus gold standard therapy, such as imipenem, a beta-lactam with aminoglucoside and imidazole or clindamycin or with broad spectrum beta-lactam and other inhibitors or beta-lactamases, but our rate of cure is impressive in such a population.
Insights
Piperacillin + tazobactam effectively treated severe intra-abdominal infections in 78% of patients when combined with surgery. This antibiotic regimen showed mild side effects, suggesting it is a viable treatment option.
Area of Science:
- Infectious Diseases
- Surgical Infections
- Pharmacology
Background:
- Intra-abdominal infections (IAI) are a significant cause of morbidity and mortality.
- Severe or life-threatening IAIs require effective antimicrobial therapy alongside surgical intervention.
Purpose of the Study:
- To evaluate the efficacy and safety of piperacillin + tazobactam in treating severe intra-abdominal infections.
- To assess the cure rates and pathogen eradication in patients receiving this treatment regimen.
Main Methods:
- A limited series of 23 patients with severe or life-threatening intra-abdominal infections were treated.
- Treatment involved piperacillin + tazobactam in conjunction with adequate surgical drainage and resections.
Main Results:
- A cure rate of 78% was achieved in the patient cohort.
- Almost all targeted pathogens were eradicated.
- Side effects were primarily eosinophilia and elevated transaminases, none severe.
Conclusions:
- Piperacillin + tazobactam, combined with appropriate surgical management, is an acceptable treatment for severe intra-abdominal infections.
- The observed cure rate is impressive for this patient population.
- Further comparative trials against gold standard therapies are warranted.